Quantum Biopharma Signs an Agreement With Ingenu CRO to Conduct a Clinical Study to Observe Disease Progression in Patients With Primary Progressive Multiple Sclerosis
Quantum Biopharma Signs an Agreement With Ingenu CRO to Conduct a Clinical Study to Observe Disease Progression in Patients With Primary Progressive Multiple Sclerosis
Zeeshan Saeed TORONTO, ON / ACCESSWIRE / September 9, 2024 / Quantum BioPharma Ltd. (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announces that through its subsidiary, HUGE Biopharma Australia Pty Ltd., it entered into an agreement with Ingenu CRO Pty Ltd on August 13, 2024 to conduct a clinical study to observe and quantify disease progression in patients with primary progressive multiple sclerosis. This study will facilitate a future phase 2 clinical trial with Lucid-21-302 (Lucid-MS).
安大略省多伦多/ACCESSWIRE/2024年9月9日/致力于建立创新资产和生物技术解决方案组合的生物制药公司量子生物制药有限公司（纳斯达克股票代码：QNTM）（FRA: 0K91）（“Quantum BioPharma” 或 “公司”）今天宣布，它通过其子公司HUGE Biopharma Australia Pty Ltd.（纳斯达克股票代码：QNTM）（FRA: 0K91）（“量子生物制药” 或 “公司”）今天宣布，它通过其子公司HUGE Biopharma Australia Pty Ltd. 2024年8月13日与Ingenu CRO Pty Ltd达成协议，进行一项临床研究，以观察和量化原发性进行性多发性硬化症患者的疾病进展。这项研究将促进未来使用Lucid-21-302（Lucid-MS）进行2期临床试验。
"We are very pleased to be working with Ingenu CRO to conduct this observational study in patients with multiple sclerosis. This is an important study which advances our multiple sclerosis research program and moves us closer to initiating a phase 2 clinical trial with Lucid-21-302," said Dr. Andrzej Chruscinski, Vice-President, Scientific and Clinical Affairs at Quantum Biopharma.
“我们很高兴与Ingenu CRO合作，对多发性硬化症患者进行这项观察性研究。这是一项重要的研究，它推进了我们的多发性硬化症研究计划，使我们更接近启动Lucid-21-302的2期临床试验。” Quantum Biopharma负责科学和临床事务的副总裁安德烈·赫鲁辛斯基博士说。
Contact Information
联系信息
Zeeshan Saeed
Founder, CEO and Executive Co-Chairman of the Board
zsaeed@quantumbiopharma.com
416-854-8884
Zeeshan Saeed
创始人、首席执行官兼董事会执行联席主席
zsaeed@quantumbiopharma.com
416-854-8884
SOURCE: Quantum Biopharma Ltd.
来源：量子生物制药有限公司
